Filing context and reporting period
The provided filing is Aeglea BioTherapeutics, Inc.’s Form 10-K for the fiscal year ended December 31, 2022, filed March 2, 2023. The request metadata identifies Spyre Therapeutics, Inc.; the filing text identifies the registrant as Aeglea BioTherapeutics, Inc. Investors should verify the issuer identity and any subsequent corporate name or business changes.
Aeglea was a clinical-stage biotechnology company developing human enzyme therapeutics for rare metabolic diseases. Its principal programs were pegtarviliase for Classical Homocystinuria and pegzilarginase for Arginase 1 Deficiency. It had no approved products and generated no product-sales revenue.
Financial performance and position
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Total revenue | $2.3 million | $18.7 million | Down 88% |
| Research and development expense | $58.6 million | $57.1 million | Up 3% |
| General and administrative expense | $28.5 million | $27.3 million | Up 4% |
| Total operating expenses | $87.1 million | $84.4 million | Up 3% |
| Loss from operations | $84.8 million | $65.6 million | Loss increased 29% |
| Net loss | $83.8 million | $65.8 million | Loss increased 27% |
| Basic and diluted loss per share | $0.99 | $1.00 | Improved slightly |
| Operating cash flow | $(80.1) million | $(53.7) million | Cash use increased |
- 2022 revenue consisted of $2.3 million of development-fee revenue under the Immedica agreement; no license revenue was recognized in 2022 versus $12.0 million in 2021.
- Cash, cash equivalents, marketable securities and restricted cash totaled $57.3 million at December 31, 2022, including $34.9 million of cash and cash equivalents, $20.8 million of marketable securities and $1.6 million of restricted cash.
- Working capital was $47.6 million, while accumulated deficit was $425.6 million.
- Investing activities provided $57.0 million, primarily reflecting maturities of marketable securities. Financing activities provided $42.7 million, principally from the May 2022 registered direct offering.
- The company reported no debt or credit facility, although it had operating and finance lease liabilities and approximately $6.1 million of future operating lease payments through April 2028.
- Stock-based compensation expense was $7.1 million. The company had 65.4 million common shares outstanding at December 31, 2022 and 28.9 million outstanding pre-funded warrants exercisable at $0.0001 per share.
Material changes from the prior comparable period
- Revenue declined substantially because the $12.0 million license component of the Immedica arrangement was recognized in 2021, while 2022 revenue primarily reflected ongoing development services.
- Net loss widened by $18.0 million, driven primarily by lower revenue and modestly higher operating expenses.
- Operating cash use increased by $26.4 million to $80.1 million.
- R&D spending increased modestly, including higher costs for pegzilarginase trial closeout and its open-label extension, AGLE-325 development and personnel, partly offset by lower pegtarviliase toxicology and preclinical costs.
- The company raised approximately $42.9 million net in May 2022 through common stock and pre-funded warrants. The filing also stated that $60.0 million remained available under its at-the-market facility as of the filing date.
Clinical, regulatory and strategic outlook
- Pegtarviliase remained in a Phase 1/2 trial for Classical Homocystinuria. The first two dose cohorts were completed, and two patients in the third cohort had completed dosing by November 2022. The FDA placed enrollment of patients younger than 18 on partial clinical hold because the protocol did not adequately support prospective direct clinical benefit; an Australian ethics committee sought to align with that restriction.
- Pegzilarginase achieved the PEACE Phase 3 primary endpoint, including a reported 76.7% reduction in mean plasma arginine versus placebo. However, key mobility endpoints did not achieve nominal statistical significance.
- The FDA issued a Refuse to File letter for the pegzilarginase BLA in June 2022, requesting additional effectiveness evidence, including evidence linking arginine reduction to clinical benefit or clinically meaningful treatment effects, as well as additional Chemistry, Manufacturing and Controls information. The company was continuing discussions regarding a potential resubmission.
- The EMA validated Immedica’s marketing authorization application for pegzilarginase in August 2022; review was ongoing, with a potential decision anticipated in late 2023 according to the filing.
- Under the Immedica agreement, Aeglea received a $21.5 million upfront payment in 2021, was eligible for approximately $120.8 million of regulatory and commercial milestones, and was entitled to royalties in the mid-20% range on net sales in the licensed territories.
- In January 2023, after year-end, the company announced that it was halting work on preclinical pipeline candidates, including AGLE-325, and would evaluate strategic options.
- Management stated that existing liquidity was expected to fund operations into the fourth quarter of 2023. Both management and the independent auditor disclosed substantial doubt about the company’s ability to continue as a going concern within one year after issuance of the financial statements.
Key risks and unusual items
- The company had recurring losses, no product revenue and no committed external source of funding; additional equity, debt, collaboration or strategic financing was required to continue operations beyond the projected cash runway.
- Clinical and regulatory risk was elevated, particularly the FDA’s concerns regarding the clinical meaningfulness of pegzilarginase efficacy data and the partial pediatric hold for pegtarviliase.
- The company relied on third-party contract research and manufacturing organizations and had no redundant supply arrangement for drug substance.
- COVID-19, inflation, rising interest rates, financial-market volatility, supply-chain disruption and geopolitical events could delay trials, manufacturing or financing.
- The company received a Nasdaq deficiency notice in January 2023 because its common stock had traded below the $1.00 minimum bid price for 30 consecutive trading days. The initial compliance period extended to July 12, 2023, subject to possible further relief.
- A large portion of potential dilution arose from outstanding pre-funded warrants, which could be exercised for nominal or no additional cash consideration.
Facts investors should verify
- Confirm whether the relevant issuer is Aeglea BioTherapeutics or Spyre Therapeutics and reconcile any subsequent name change, merger, reverse merger or business transformation.
- Verify the post-year-end cash balance, financing activity and actual cash runway, because the disclosed runway extended only into the fourth quarter of 2023.
- Track the FDA’s requirements and the status of any pegzilarginase BLA resubmission or additional clinical studies.
- Track EMA review and any approval, reimbursement or commercialization developments under the Immedica partnership.
- Assess dilution from the 28.9 million pre-funded warrants, the at-the-market facility and any subsequent equity offerings.
- Verify whether Nasdaq listing compliance was restored and whether any reverse stock split or other capital-structure action occurred.